Clinical Trials Browser

Phase 2 × Medulloblastoma × Irinotecan × Clear all

Ependymoma, Medulloblastoma, Recurrence

NCT04743661 2026-02-05

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

Phase 2 Active not recruiting

62 enrolled

CNS

Ependymoma, Medulloblastoma

NCT03709680 2025-01-14

Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors

Phase 2 Active not recruiting

128 enrolled

CNSSarcoma

Diffuse Intrinsic Pontine Glioma, Bone Neoplasms, Medulloblastoma, Neoplasms, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Rhabdoid Tumor

NCT01217437 2021-07-23

Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors

Phase 2 Completed

108 enrolled 14 charts

CNS

Medulloblastoma, Pinealoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral, Neuroectodermal Tumors, Primitive

NCT00381797 2017-11-28

Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma

Phase 2 Completed

97 enrolled 35 charts

CNS

Familial ependymoma, Medulloblastoma, Oligodendroglioma, Spinal Cord Neoplasms

NCT00004078 2013-06-14

Irinotecan in Treating Children With Refractory Solid Tumors

Phase 2 Completed

181 enrolled

CNSSarcoma

Familial ependymoma, Astrocytoma, Medulloblastoma, Neuroblastoma, Oligodendroglioma, Osteosarcoma, Choroid Plexus Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral, Optic Nerve Glioma

NCT00404495 2012-04-18

Combination of Irinotecan and Temozolomide in Children With Brain Tumors.

Phase 2 Completed

83 enrolled 12 charts

CNS

Glioma, Medulloblastoma

Clinical Trials

MEMMAT

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors

Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors

Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma

Irinotecan in Treating Children With Refractory Solid Tumors

Combination of Irinotecan and Temozolomide in Children With Brain Tumors.